Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis
NCT ID: NCT02230696
Last Updated: 2021-10-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
951 participants
INTERVENTIONAL
2014-08-31
2015-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test Product
Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray - Perrigo
Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray
137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
Reference Product
Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray - Meda
Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray
137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
Placebo Product
Placebo nasal spray
Placebo nasal spray
Placebo nasal spray
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray
137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray
137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
Placebo nasal spray
Placebo nasal spray
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female between 12 to 65 years of age, inclusive.
3. Females of childbearing potential willing to use an acceptable form of birth control during the study.
4. Moderate-to-severe allergic rhinitis.
5. At Visits 1 and 2 have instantaneous and reflective symptom scores sufficient enough to qualify for continued participation in the study
6. Subject must have a history (for 2 or more seasons) of seasonal allergy to at least one allergen known to be present during the study season.
7. Subject must be in general good health with no clinically significant disease or medical procedure other than allergic rhinitis within various time periods prior to Visit 1.
8. Subject must be willing and able to understand and comply with the requirements of the study
Exclusion Criteria
2. Subject has a history of hypersensitivity or allergy to any ingredient in the drug products.
3. Subject has any condition or abnormality of the upper airway that, in the opinion of the Investigator, could interfere with administration of the product, evaluation of the subject's condition, or other aspect of the trial.
4. The presence of any nasal mucosal crusting, erosion, ulceration, nasal septum perforation, or any kind of blockage of the nasal passages at screening or randomization.
5. Subject has asthma or a history of asthma requiring chronic treatment within two years of Visit 1.
6. Treatment for oral Candidiasis within 30 days of starting the study, or a current oral Candidiasis infection.
7. Subject has had recent exposure (30 days) or is at risk of being exposed to chicken pox or measles.
8. Subjects with any untreated fungal, bacterial, systemic viral infections within the previous 30 days.
9. Use of various therapies within the given time period prior to Visit 1 and throughout the study.
10. Initiation of hormone replacement therapy during the study.
11. Initiation of immunotherapy during the study, or changes in dosage or frequency of immunotherapy within the 30 days preceding Visit 1.
12. Subject has received immune-system therapy or peptide immunotherapy of any form.
13. Subject had desensitization therapy to the seasonal allergen that is causing their allergic rhinitis within the previous 6 months.
14. Subject presented with conjunctivitis or any other eye signs/symptoms that are not related to the diagnosis of SAR.
15. Clinically relevant abnormal physical findings or medication use within 1 week of randomization, which, in the opinion of the investigator, might interfere with the conduct or results of the study or place the prospective subject at increased risk.
16. Subjects being treated with a product containing a sympathomimetic agent.
17. Subject has previously enrolled in this study or is enrolled in this study with another participating investigator site.
18. Subject is concurrently participating in another investigational study or using any investigational drug (or biologic) or device.
19. Subject plans or anticipates travel outside the local allergen area at any point in the study.
20. History of unresponsiveness to steroid nasal sprays for SAR symptoms.
21. Employee (or employee's family member) of the research center or private practice.
22. If the subject has a smoking history of greater than 10 pack years or has recently started or re-started smoking within the past 2 years
12 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Padagis LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Atlanta Allergy & Asthma Clinic, PA
Stockbridge, Georgia, United States
Clinical Research Atlanta (CRA)
Stockbridge, Georgia, United States
Family Allergy and Asthma Research Institute
Louisville, Kentucky, United States
Chesapeake Clinical Research, Inc.
Baltimore, Maryland, United States
NEMRA Northeast Medical Research Associates, Inc
North Dartmouth, Massachusetts, United States
Clinical Research Institute, Inc.
Minneapolis, Minnesota, United States
Clinical Research Institute LLC
Minneapolis, Minnesota, United States
Clinical Research of the Ozarks, Inc.
Columbia, Missouri, United States
Clinical Research of the Ozarks, Inc.
Rolla, Missouri, United States
The Clinical Research Center, LLC
St Louis, Missouri, United States
Princeton Center for Clinical Research
Skillman, New Jersey, United States
Island Medical Research, P.C.
Rockville Centre, New York, United States
Allergy and Asthma Center of NC
High Point, North Carolina, United States
North Carolina Clinical Research
Raleigh, North Carolina, United States
Toledo Center for Clinical Research
Sylvania, Ohio, United States
Allergy, Asthma & Clinical Research Center
Oklahoma City, Oklahoma, United States
Vital Prospects Clinical Research Institute, P.C.
Tulsa, Oklahoma, United States
National Allergy, Asthma & Urticaria Centers of Charleston
North Charleston, South Carolina, United States
New Phase Research and Development
Knoxville, Tennessee, United States
ISIS Clinical Research, LLC
Austin, Texas, United States
Sirius Clinical Research LLC
Austin, Texas, United States
AARA Research Center
Dallas, Texas, United States
Pharmaceutical Research & Consulting Inc.
Dallas, Texas, United States
Western Sky Medical Research
El Paso, Texas, United States
Central Texas Health Research
New Braunfels, Texas, United States
Quality Research Inc.
San Antonio, Texas, United States
Diagnostics Research Group
San Antonio, Texas, United States
Sylvana Research Associates
San Antonio, Texas, United States
Allergy Asthma Research Institute
Waco, Texas, United States
The Asthma & Allergy Center - Bellevue
Bellevue, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRG-NY-14-018
Identifier Type: -
Identifier Source: org_study_id